SCHEMBL20182271

SCHEMBL20182271

CCC(/C(=C/Nc1ccc(F)c(F)c1)N=N)n1cc(-c2cncnc2OC)c2c(N)ncnc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 3/20 0.35
EIF2AK3 Q9NZJ5 2/20 0.33
AXL P30530 2/20 0.32
EGFR P00533 4/20 0.32
ABL1 P00519 3/20 0.32
ABL2 P42684 2/20 0.32
RET P07949 5/20 0.32
ALK Q9UM73 1/20 0.32
SRC P12931 2/20 0.31
KDR P35968 2/20 0.31
PIK3CD O00329 2/20 0.31
PIK3CA P42336 2/20 0.31
PIK3CB P42338 2/20 0.31
PIK3CG P48736 2/20 0.31
PRKDC P78527 2/20 0.31
TEK Q02763 1/20 0.31
HCK P08631 1/20 0.31
MTOR P42345 1/20 0.31
EPHB4 P54760 1/20 0.31
PI4KB Q9UBF8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20182191 0.93 ALK (0.34) CFTREIF2AK3AXLEGFRABL1
SCHEMBL20182222 0.91 AXL (0.34) EIF2AK3AXLEGFRABL1ABL2
SCHEMBL20182275 0.90 EGFR (0.36) EIF2AK3AXLEGFRABL1ABL2
SCHEMBL20182224 0.90 EGFR (0.39) CFTREGFRABL1ABL2RET
SCHEMBL20181916 0.89 CFTR (0.39) CFTREIF2AK3EGFRABL1ABL2
SCHEMBL20182265 0.89 NTRK1 (0.36) CFTREIF2AK3AXLEGFRABL1
SCHEMBL20182226 0.84 BTK (0.35) CFTREIF2AK3EGFRABL1ABL2
SCHEMBL20182225 0.83 CFTR (0.39) CFTRAXLEGFRABL1ABL2
SCHEMBL20182235 0.82 EIF2AK3 (0.34) EIF2AK3AXLEGFRABL1ABL2
SCHEMBL20182194 0.81 EIF2AK3 (0.36) CFTREIF2AK3EGFRABL1ABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018094137-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) 2018-05-24 WO disclosed